Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults
This trial is active, not recruiting.
|Treatments||chemotherapy, surgery, radiotherapy|
|Sponsor||Grupo Espanol de Investigacion en Sarcomas|
|Start date||April 2010|
|End date||December 2016|
|Trial size||43 participants|
|Trial identifier||NCT01696669, 2009-016027-62, GEIS-21|
Tumors of the Ewing sarcoma family (ES) affect children, adolescents and young adults. The reported incidence is 0.6 cases per million inhabitants every year. The peak incidence occurs between 10 and 20 years and it is rarely diagnosed beyond 30. The ES is a severe disease with a progression-free survival after 5 years of 60% in cases without metastasis and deadly in the majority of patients presenting metastasis. The ES is considered a systemic disease because, despite receiving an adequate local treatment, over 90% of patients deaths occur due to disseminated disease. Combined therapy of surgery, radiotherapy and chemotherapy has led to an improvement in the prognosis, achieving a survival of about 60% in most series
The MSKCC P6 protocol was developed for the treatment of high risk ES. In 2003, Kolb et al. reported the MSKCC experience after a 4-years follow-up of 68 patients who had been included from 1990 to 2001. Following the MSKCC P6 protocol, a survival rate of 82% was achieved in patients without metastasis, superior to the achieved with less intensive protocols. Following the guidelines of the MSKCC P6 protocol, in 2002 we modified the treatment schedule to create the modified P6 protocol (MP6). GEIS intends to develop MP6 as a clinical trial, which could provide the following potential advantages about current treatments:
1. Lower total dose of alkylating agents.
2. Early cardioprotection with dexrazoxane.
3. Radiotherapy adjusted to the initial response.
4. Pilot trial with the combination of Gemcitabine + Docetaxel for high-risk patients.
|United States||No locations recruiting|
|Other countries||No locations recruiting|
|Barcelona, Spain||Hospital Clínic de Barcelona||no longer recruiting|
|Barcelona, Spain||Hospital de la Santa Creu i Sant Pau||no longer recruiting|
|Barcelona, Spain||Hospital Vall d'Hebron||no longer recruiting|
|Esplugues de Llobregat, Spain||Hospital Sant Joan de Déu||no longer recruiting|
|Hospitalet de Llobregat, Spain||Institut Català d'Oncologia l'Hospitalet||no longer recruiting|
|La Laguna, Spain||Hospital Universitario de Canarias||no longer recruiting|
|Madrid, Spain||Hospital Ramón y Cajal||no longer recruiting|
|Palma de Mallorca, Spain||Hospital Son Espases||no longer recruiting|
|Zaragoza, Spain||Hospital Universitario Miguel Servet||no longer recruiting|
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Progression Free Survival
time frame: Assessment of the progression free survival in all the patients enrolled in the study 3 years after the completion of the treatment under study.
Objective response rate (ORR)
time frame: two months
Assessment of disease progression
time frame: to reach an index of disease progression < 20% for high risk patients during the maintenance phase with Gemcitabine + Docetaxel.
evaluate the toxicity and tolerance to the treatment Gemcitabine + Docetaxel in high risk patients, and toxicity and tolerance of mP6 treatment in all patients.
time frame: 12 months
Assessment of bone marrow condition.
time frame: 24 months
Study the impact of patients treated with Cardioxane in cardioprotection
time frame: 6 months
Male or female participants up to 40 years old.
- Patients with Ewing's Sarcoma in which the molecular analysis has been performed in one of the 2 reference laboratories of the study and the EWS gene rearrangement has been confirmed by RT-PCR in the Hospital Sant Joan de Déu de Barcelona, or by fluorescence in situ hybridization (FISH) in the Cancer Research Center of Salamanca.
- High-risk patients will be those patients with metastases, patients with primary tumor in pelvis or axial bones and patients with (micro) metastases in bone marrow detected by the molecular study. The remaining patients will be considered as standard risk. Lung nodules identified by CT-scan with diameter > 5 mm will be considered metastatic. Nodules ≤ 5 mm will be biopsied.
- Age ≤ 40 years.
- Adequate renal and hepatic function , defined as calculated creatinine clearance > 60 ml/min, creatinine, total bilirubin, AST and/or ALT < 1,5 times the upper limit of normal (ULN).
- Normal cardiac function defined by echocardiography, or ejection fraction ≥ 55%.
- ECOG performance status 0 - 1 (Appendix VIII).
- Informed consent form signed by parents, guardians or the patient (if over 18 years), prior to the start of treatment.
- Patients of childbearing age (both men and women) must use effective contraceptive methods before study entry and during the realization of it. Effective contraceptive methods for both women and men should be extended to 6 months after stopping the treatment under study. Pregnancy must be excluded by urine test (negative pregnancy test) prior to the inclusion in the study.
- Pregnancy or breastfeeding.
- Active infection or other severe concomitant diseases.
- Severe psychiatric conditions that make impossible to obtain the signed informed consent form or limit the treatment compliance.
- Concurrent treatment with other experimental drugs within 30 days prior to study entry.
- History of previous cancer diagnosed or treated in the past 5 years except basal cell carcinoma, cervical carcinoma in situ or superficial bladder cancer.
|Official title||Phase 2, Open-label, Uncontrolled, Multicenter and Prospective Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults|
Call for more information